Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes

Molecular and Cellular Endocrinology

Volumn 394, Issue 1-2, 2014, Pages 13-20

  Bernardi, Stella ^a,b   Fabris, Bruno ^c   Thomas, Merlin ^b   Toffoli, Barbara ^d   Tikellis, Christos ^b   Candido, Riccardo ^e   Catena, Cristiana ^f   Mulatero, Paolo ^g   Barbone, Fabio ^f   Radillo, Oriano ^d   Zauli, Giorgio ^d   Secchiero, Paola ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c UNIVERSITY OF TRIESTE   (Italy)

^d INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^e Diabetological Centre   (Italy)

^f SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^g UNIVERSITY OF TURIN   (Italy)

Author keywords

Adipose tissue; High fat diet; Inflammation; Metabolic syndrome; Osteoprotegerin

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; OSTEOPROTEGERIN; GLUCOSE BLOOD LEVEL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; LIPID DIET; MALE; METABOLIC SYNDROME X; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; TISSUE LEVEL; ADVERSE EFFECTS; ANIMAL; BLOOD; BODY MASS; C57BL MOUSE; CASE CONTROL STUDY; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADIPOSE TISSUE; ADULT; ANIMALS; BLOOD GLUCOSE; BODY MASS INDEX; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIET, HIGH-FAT; FEMALE; HUMANS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MICE; MICE, INBRED C57BL; MIDDLE AGED; OBESITY; OSTEOPROTEGERIN; TRIGLYCERIDES;

EID: 84904334547     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2014.06.004     Document Type: Article

References (55)

1. Akinci B., Celtik A., Yuksel F., Genc S., Yener S., Secil M., Ozcan M.A., Yesil S. Increased osteoprotegerin levels in women with previous gestational diabetes developing metabolic syndrome. Diabetes Res. Clin. Pract. 2011, 91:26-31.
2. Alberti K.G., Zimmet P., Shaw J. Metabolic syndrome - a new world-wide definition. A Consensus statement from the international diabetes federation. Diabet. Med. 2006, 23:469-480.
3. An J.J., Han D.H., Kim D.M., Kim S.H., Rhee Y., Lee E.J., Lim S.K. Expression and regulation of osteoprotegerin in adipose tissue. Yonsei Med. J. 2007, 48:765-772.
4. Ashley D.T., O'Sullivan E.P., Davenport C., Devlin N., Crowley R.K., McCaffrey N., Moyna N.M., Smith D., O'Gorman D.J. Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects. Metabolism 2011, 60:994-1000.
5. Augoulea A., Vrachnis N., Lambrinoudaki I., Dafopoulos K., Iliodromiti Z., Daniilidis A., Varras M., Alexandrou A., Deligeoroglou E., Creatsas G. Osteoprotegerin as a marker of atherosclerosis in diabetic patients. Int. J. Endocrinol. 2013, 2013:182060.
6. Bastard J.P., Jardel C., Bruckert E., Blondy P., Capeau J., Laville M., Vidal H., Hainque B. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J. Clin. Endocrinol. Metab. 2000, 85:3338-3342.
7. Bernardi S., Milani D., Fabris B., Secchiero P., Zauli G. TRAIL as biomarker and potential therapeutic tool for cardiovascular diseases. Curr. Drug Targets 2012, 13:1215-1221.
8. Bernardi S., Zauli G., Tikellis C., Candido R., Fabris B., Secchiero P., Cooper M.E., Thomas M.C. TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation. Clin. Sci. (Lond.) 2012, 123:547-555.
9. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
10. Browner W.S., Lui L.Y., Cummings S.R. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J. Clin. Endocrinol. Metab. 2001, 86:631-637.
11. Buettner R., Scholmerich J., Bollheimer L.C. High-fat diets: modeling the metabolic disorders of human obesity in rodents. Obesity (Silver Spring) 2007, 15:798-808.
12. Candido R., Toffoli B., Corallini F., Bernardi S., Zella D., Voltan R., Grill V., Celeghini C., Fabris B. Human full-length osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo. J. Vasc. Res. 2010, 47:252-261.
13. Carr D.B., Utzschneider K.M., Hull R.L., Kodama K., Retzlaff B.M., Brunzell J.D., Shofer J.B., Fish B.E., Knopp R.H., Kahn S.E. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004, 53:2087-2094.
14. Collins G.S., Mallett S., Omar O., Yu L.M. Developing risk prediction models for type 2 diabetes: a systematic review of methodology and reporting. BMC Med. 2011, 9:103.
15. Dallmeier D., Larson M.G., Vasan R.S., Keaney J.F., Fontes J.D., Meigs J.B., Fox C.S., Benjamin E.J. Metabolic syndrome and inflammatory biomarkers: a community-based cross-sectional study at the Framingham Heart Study. Diabetol. Metab. Syndr. 2012, 4:28.
16. Di Gregorio G.B., Yao-Borengasser A., Rasouli N., Varma V., Lu T., Miles L.M., Ranganathan G., Peterson C.A., McGehee R.E., Kern P.A. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes 2005, 54:2305-2313.
17. Esposito K., Pontillo A., Di Palo C., Giugliano G., Masella M., Marfella R., Giugliano D. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003, 289:1799-1804.
18. Fraulob J.C., Ogg-Diamantino R., Fernandes-Santos C., Aguila M.B., Mandarim-de-Lacerda C.A. A mouse model of metabolic syndrome: insulin resistance, fatty liver and non-alcoholic fatty pancreas disease (NAFPD) in C57BL/6 mice fed a high fat diet. J. Clin. Biochem. Nutr. 2010, 46:212-223.
19. Gallou-Kabani C., Vige A., Gross M.S., Rabes J.P., Boileau C., Larue-Achagiotis C., Tome D., Jais J.P., Junien C. C57BL/6J and A/J mice fed a high-fat diet delineate components of metabolic syndrome. Obesity (Silver Spring) 2007, 15:1996-2005.
20. Gannage-Yared M.H., Fares F., Semaan M., Khalife S., Jambart S. Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population. Clin. Endocrinol. (Oxf.) 2006, 64:652-658.
21. Gannage-Yared M.H., Yaghi C., Habre B., Khalife S., Noun R., Germanos-Haddad M., Trak-Smayra V. Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study. Eur. J. Endocrinol. 2008, 158:353-359.
22. Guilherme A., Virbasius J.V., Puri V., Czech M.P. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell Biol. 2008, 9:367-377.
23. Harith H.H., Morris M.J., Kavurma M.M. On the TRAIL of obesity and diabetes. Trends Endocrinol. Metab. 2013, 24:578-587.
24. Hofbauer L.C., Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004, 292:490-495.
25. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
26. Kahn, R., Buse, J., Ferrannini, E., Stern, M., American Diabetes Association and European Association for the Study of Diabetes, 2005. The Metabolic Syndrome: Time for a Critical Appraisal: Joint Statement from the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, vol. 28, pp. 2289-2304.
27. Kanda H., Tateya S., Tamori Y., Kotani K., Hiasa K., Kitazawa R., Kitazawa S., Miyachi H., Maeda S., Egashira K., Kasuga M. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Invest. 2006, 116:1494-1505.
28. Kiechl S., Wittmann J., Giaccari A., Knoflach M., Willeit P., Bozec A., Moschen A.R., Muscogiuri G., Sorice G.P., Kireva T., Summerer M., Wirtz S., Luther J., Mielenz D., Billmeier U., Egger G., Mayr A., Oberhollenzer F., Kronenberg F., Orthofer M., Penninger J.M., Meigs J.B., Bonora E., Tilg H., Willeit J., Schett G. Blockade of receptor activator of nuclear factor-kappaB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat. Med. 2013, 19:358-363.
29. Malyankar U.M., Scatena M., Suchland K.L., Yun T.J., Clark E.A., Giachelli C.M. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J. Biol. Chem. 2000, 275:20959-20962.
30. Mangan S.H., Van Campenhout A., Rush C., Golledge J. Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2. Cardiovasc. Res. 2007, 76(3):494-505.
31. Nabipour I., Kalantarhormozi M., Larijani B., Assadi M., Sanjdideh Z. Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women. Metabolism 2010, 59:742-747.
32. Neels J.G., Olefsky J.M. Inflamed fat: what starts the fire?. J. Clin. Invest. 2006, 116:33-35.
33. Pepene C.E., Ilie I.R., Marian I., Duncea I. Circulating osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction. Eur. J. Endocrinol. 2011, 164:61-68.
34. Pitombo C., Araujo E.P., De Souza C.T., Pareja J.C., Geloneze B., Velloso L.A. Amelioration of diet-induced diabetes mellitus by removal of visceral fat. J. Endocrinol. 2006, 191:699-706.
35. Rasmussen L.M., Tarnow L., Hansen T.K., Parving H.H., Flyvbjerg A. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur. J. Endocrinol. 2006, 154:75-81.
36. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
37. Rossmeisl M., Rim J.S., Koza R.A., Kozak L.P. Variation in type 2 diabetes-related traits in mouse strains susceptible to diet-induced obesity. Diabetes 2003, 52:1958-1966.
38. Ryan A.S., Nicklas B.J. Reductions in plasma cytokine levels with weight loss improve insulin sensitivity in overweight and obese postmenopausal women. Diabetes Care 2004, 27:1699-1705.
39. Sabio G., Das M., Mora A., Zhang Z., Jun J.Y., Ko H.J., Barrett T., Kim J.K., Davis R.J. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 2008, 322:1539-1543.
40. Schrader J., Rennekamp W., Niebergall U., Schoppet M., Jahr H., Brendel M.D., Horsch D., Hofbauer L.C. Cytokine-induced osteoprotegerin expression protects pancreatic beta cells through p38 mitogen-activated protein kinase signalling against cell death. Diabetologia 2007, 50:1243-1247.
41. Secchiero P., Corallini F., Pandolfi A., Consoli A., Candido R., Fabris B., Celeghini C., Capitani S., Zauli G. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am. J. Pathol. 2006, 169:2236-2244.
42. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T.M., Hill D., Pattison W., Campbell P., Sander S., Van G., Tarpley J., Derby P., Lee R., Boyle W.J. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
43. Surwit R.S., Feinglos M.N., Rodin J., Sutherland A., Petro A.E., Opara E.C., Kuhn C.M., Rebuffe-Scrive M. Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice. Metabolism 1995, 44:645-651.
44. Theoleyre S., Kwan Tat S., Vusio P., Blanchard F., Gallagher J., Ricard-Blum S., Fortun Y., Padrines M., Redini F., Heymann D. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. Biochem. Biophys. Res. Commun. 2006, 347:460-467.
45. Toffoli B., Bernardi S., Candido R., Sabato N., Carretta R., Corallini F., Secchiero P., Zauli G., Fabris B. Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets. Mol. Cell. Endocrinol. 2011, 331:136-142.
46. Toffoli B., Pickering R.J., Tsorotes D., Wang B., Bernardi S., Kantharidis P., Fabris B., Zauli G., Secchiero P., Thomas M.C. Osteoprotegerin promotes vascular fibrosis via a TGF-beta1 autocrine loop. Atherosclerosis 2011, 218:61-68.
47. Tuomilehto J., Lindstrom J., Eriksson J.G., Valle T.T., Hamalainen H., Ilanne-Parikka P., Keinanen-Kiukaanniemi S., Laakso M., Louheranta A., Rastas M., Salminen V., Uusitupa M., Finnish Diabetes Prevention Study Group Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New Engl. J. Med. 2001, 344:1343-1350.
48. Venuraju S.M., Yerramasu A., Corder R., Lahiri A. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J. Am. Coll. Cardiol. 2010, 55:2049-2061.
49. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 2003, 112:1796-1808.
50. Weisberg S.P., Hunter D., Huber R., Lemieux J., Slaymaker S., Vaddi K., Charo I., Leibel R.L., Ferrante A.W. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J. Clin. Invest. 2006, 116(1):115-124.
51. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., Sole J., Nichols A., Ross J.S., Tartaglia L.A., Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 2003, 112:1821-1830.
52. Yang W., Lu J., Weng J., Jia W., Ji L., Xiao J., Shan Z., Liu J., Tian H., Ji Q., Zhu D., Ge J., Lin L., Chen L., Guo X., Zhao Z., Li Q., Zhou Z., Shan G., He J., China National Diabetes and Metabolic Disorders Study Group Prevalence of diabetes among men and women in China. New Engl. J. Med. 2010, 362:1090-1101.
53. Zauli G., Corallini F., Bossi F., Fischetti F., Durigutto P., Celeghini C., Tedesco F., Secchiero P. Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood. 2007, 110(2):536-543.
54. Zauli G., Melloni E., Capitani S., Secchiero P. Role of full-length osteoprotegerin in tumor cell biology. Cell. Mol. Life Sci. 2009, 66:841-851.
55. Zhang J., Fu M., Myles D., Zhu X., Du J., Cao X., Chen Y.E. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett. 2002, 521:180-184.